Transfusions of blood products and cancer outcomes

Revista Espanola de Anestesiologia y Reanimacion

Volumn 62, Issue 8, 2015, Pages 461-467

  Velasquez J F ^a   Cata, J P ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b OUTCOMES RESEARCH CONSORTIUM   (United States)

Author keywords

Blood transfusions; Neoplasms; Recurrence

Indexed keywords

CYTOKINE; SIGNAL PEPTIDE;

ADVERSE EFFECTS; ANEMIA; BLOOD; BLOOD TRANSFUSION; CARCINOMA; COMPLICATION; DISEASE FREE SURVIVAL; ERYTHROCYTE TRANSFUSION; HUMAN; IMMUNOLOGY; LEUKOCYTE; META ANALYSIS (TOPIC); METASTASIS; NATURAL KILLER CELL; NEOPLASMS; PLASMA; PROGNOSIS; RECURRENT DISEASE; SECRETION (PROCESS); STATISTICS AND NUMERICAL DATA; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME;

ANEMIA; BLOOD TRANSFUSION; CARCINOMA; CYTOKINES; DISEASE-FREE SURVIVAL; ERYTHROCYTE TRANSFUSION; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KILLER CELLS, NATURAL; LEUKOCYTES; META-ANALYSIS AS TOPIC; NEOPLASM METASTASIS; NEOPLASMS; PLASMA; PLATELET TRANSFUSION; PROGNOSIS; RECURRENCE; TREATMENT OUTCOME;

EID: 84941313611     PISSN: 00349356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redar.2015.02.013     Document Type: Article

References (48)

1. Dunn A., Carter J., Carter H. Anemia at the end of life: prevalence, significance, and causes in patients receiving palliative care. J Pain Symptom Manag 2003, 26:1132-1139.
2. Uceda Torres M.E., Rodríguez Rodríguez J.N., Sánchez Ramos J.L., Alvarado Gómez F. Transfusion in palliative cancer patients: a review of the literature. J Palliat Med 2014, 17:88-104.
3. Ludwig H., Van Belle S., Barrett-Lee P., Birgegård G., Bokemeyer C., Gascón P., et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004, 40:2293-2306.
4. Rodgers G.M., Becker P.S., Blinder M., Cella D., Chanan-Khan A., Cleeland C., et al. Cancer- and chemotherapy-induced anemia. J Natl Compr Cancer Netw 2012, 10:628-653.
5. Cata J.P., Wang H., Gottumukkala V., Reuben J., Sessler D.I. Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions. Br J Anaesth 2013, 110:690-701.
6. De Almeida J.P., Vincent J.L., Barbosa Gomes Galas F.R., Marinho de Almeida E.P., Fukushima J.T., Osawa E.A., et al. Transfusion requirements in surgical oncology patients: a prospective, randomized controlled trial. Anesthesiology 2015, 122:29-38.
7. Berardi R., Brunelli A., Tamburrano T., Verdecchia L., Onofri A., Zuccatosta L., et al. Perioperative anemia and blood transfusions as prognostic factors in patients undergoing resection for non-small cell lung cancers. Lung Cancer 2005, 49:371-376.
8. Panagopoulos N.D., Karakantza M., Koletsis E., Apostolakis E., Sakellaropoulos G.C., Filos K.S., et al. Influence of blood transfusions and preoperative anemia on long-term survival in patients operated for non-small cell lung cancer. Lung Cancer 2008, 62:273-280.
9. Rink M., Sharifi N., Fritsche H.M., Aziz A., Miller F., Kluth L.A., et al. Impact of preoperative anemia on oncologic outcomes of upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol 2014, 191:316-322.
10. Semenza G.L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002, 8:S62-S67.
11. Nakamura T., Grimer R., Gaston C., Carter S., Tillman R., Abudu A., et al. The relationship between pretreatment anaemia and survival in patients with adult soft tissue sarcoma. J Orthop Sci 2013, 18:987-993.
12. Loor G., Rajeswaran J., Li L., Sabik J.F., Blackstone E.H., McCrae K.R., et al. The least of 3 evils: exposure to red blood cell transfusion, anemia, or both?. J Thorac Cardiovasc Surg 2013, 146. 1480-1487.e6.
13. van de Watering L.M., Brand A., Houbiers J.G., Klein Kranenbarg W.M., Hermans J., van de Velde C., et al. Perioperative blood transfusions, with or without allogeneic leucocytes, relate to survival, not to cancer recurrence. Br J Surg 2001, 88:267-272.
14. Lange M.M., van Hilten J.A., van de Watering L.M., Bijnen B.A., Roumen R.M., Putter H., et al. Leucocyte depletion of perioperative blood transfusion does not affect long-term survival and recurrence in patients with gastrointestinal cancer. Br J Surg 2009, 96:734-740.
15. Skanberg J., Lundholm K., Haglind E. Effects of blood transfusion with leucocyte depletion on length of hospital stay, respiratory assistance and survival after curative surgery for colorectal cancer. Acta Oncol 2007, 46:1123-1130.
16. Cata J.P., Klein E.A., Hoeltge G.A., Dalton J.E., Mascha E., O'Hara J., et al. Blood storage duration and biochemical recurrence of cancer after radical prostatectomy. Mayo Clin Proc 2011, 86:120-127.
17. Paul R., Schmid R., Busch R., van Randenborgh H., Alschibaja M., Scholer S., et al. Influence of blood transfusions during radical retropubic prostatectomy on disease outcome. Urology 2006, 67:137-141.
18. Mortensen F.V., Jensen L.S., Sorensen H.T., Pedersen L. Cause-specific mortality associated with leukoreduced, buffy coat-depleted, or no blood transfusion after elective surgery for colorectal cancer: a posttrial 15-year follow-up study. Transfusion (Paris) 2011, 51:259-263.
19. Moir M.S., Samy R.N., Hanasono M.M., Terris D.J. Autologous and heterologous blood transfusion in head and neck cancer surgery. Arch Otolaryngol Head Neck Surg 1999, 125:864-868.
20. Waters J.H., Yazer M., Chen Y.F., Kloke J. Blood salvage and cancer surgery: a meta-analysis of available studies. Transfusion (Paris) 2012, 52:2167-2173.
21. Amato A., Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev 2006, CD005033.
22. Acheson A.G., Brookes M.J., Spahn D.R. Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery: a systematic review and meta-analysis. Ann Surg 2012, 256:235-244.
23. Yao H.S., Wang Q., Wang W.J., Hu Z.Q. Intraoperative allogeneic red blood cell transfusion in ampullary cancer outcome after curative pancreatoduodenectomy: a clinical study and meta-analysis. World J Surg 2008, 32:2038-2046.
24. Kneuertz P.J., Patel S.H., Chu C.K., Maithel S.K., Sarmiento J.M., Delman K.A., et al. Effects of perioperative red blood cell transfusion on disease recurrence and survival after pancreaticoduodenectomy for ductal adenocarcinoma. Ann Surg Oncol 2011, 18:1327-1334.
25. Luan H., Ye F., Wu L., Zhou Y., Jiang J. Perioperative blood transfusion adversely affects prognosis after resection of lung cancer: a systematic review and a meta-analysis. BMC Surg 2014, 14:34.
26. Wang T., Luo L., Huang H., Yu J., Pan C., Cai X., et al. Perioperative blood transfusion is associated with worse clinical outcomes in resected lung cancer. Ann Thorac Surg 2014, 97:1827-1837.
27. Woolley A.L., Hogikyan N.D., Gates G.A., Haughey B.H., Schechtman K.B., Goldenberg J.L. Effect of blood transfusion on recurrence of head and neck carcinoma: retrospective review and meta-analysis. Ann Otol Rhinol Laryngol 1992, 101:724-730.
28. Ling F.C., Hoelscher A.H., Vallbohmer D., Schmidt D., Picker S., Gathof B.S., et al. Leukocyte depletion in allogeneic blood transfusion does not change the negative influence on survival following transthoracic resection for esophageal cancer. J Gastrointest Surg 2009, 13:581-586.
29. Yeoh T.Y., Scavonetto F., Weingarten T.N., Karnes R.J., van Buskirk C.M., Hanson A.C., et al. Perioperative allogeneic nonleukoreduced blood transfusion and prostate cancer outcomes after radical prostatectomy. Transfusion (Paris) 2014, 54:2175-2181.
30. Boehm K., Beyer B., Tennstedt P., Schiffmann J., Budaeus L., Haese A., et al. No impact of blood transfusion on oncological outcome after radical prostatectomy in patients with prostate cancer. World J Urol 2014 Jul 3, [Epub ahead of print].
31. Linder B.J., Frank I., Cheville J.C., Tollefson M.K., Thompson R.H., Tarrell R.F., et al. The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol 2013, 63:839-845.
32. Linder B.J., Thompson R.H., Leibovich B.C., Cheville J.C., Lohse C.M., Gastineau D.A., et al. The impact of perioperative blood transfusion on survival after nephrectomy for non-metastatic renal cell carcinoma (RCC). BJU Int 2013, 114:368-374.
33. Kluth L.A., Xylinas E., Rieken M., El Ghouayel M., Sun M., Karakiewicz P.I., et al. Impact of peri-operative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder. BJU Int 2014, 113:393-398.
34. Rieken M., Schubert T., Xylinas E., Kluth L., Roupret M., Trinh Q.D., et al. Association of perioperative blood transfusion with oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur J Surg Oncol 2014, 40:1693-1699.
35. De Oliveira G.S., Schink J.C., Buoy C., Ahmad S., Fitzgerald P.C., McCarthy R.J. The association between allogeneic perioperative blood transfusion on tumour recurrence and survival in patients with advanced ovarian cancer. Transfus Med 2012, 22:97-103.
36. Morgenstern L., Dowdy S., Martin J., Lemens M., McGree M., Weaver A., et al. The impact of perioperative packed red blood cell transfusion on survival in epithelial ovarian cancer. Gynecol Oncol 2012, 127:S27.
37. Eickhoff J.H., Andersen J., Laybourn C. Perioperative blood transfusion does not promote recurrence and death after mastectomy for breast cancer. The Danish Breast Cancer Cooperative Group. Br J Surg 1991, 78:1358-1361.
38. Mirhashemi R., Averette H.E., Deepika K., Estape R., Angioli R., Martin J., et al. The impact of intraoperative autologous blood transfusion during type III radical hysterectomy for early-stage cervical cancer. Am J Obstet Gynecol 1999, 181:1310-1315.
39. Schiffer C.A., Anderson K.C., Bennett C.L., Bernstein S., Elting L.S., Goldsmith M., et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001, 19:1519-1538.
40. Buergy D., Wenz F., Groden C., Brockmann M.A. Tumor-platelet interaction in solid tumors. Int J Cancer 2012, 130:2747-2760.
41. Digklia A., Voutsadakis I.A. Thrombocytosis as a prognostic marker in stage III and IV serous ovarian cancer. Obstet Gynecol Sci 2014, 57:457-463.
42. Kim M., Chang H., Yang H.C., Kim Y.J., Lee C.T., Lee J.H., et al. Preoperative thrombocytosis is a significant unfavorable prognostic factor for patients with resectable non-small cell lung cancer. World J Surg Oncol 2014, 12:37.
43. Kubo S., Kinoshita H., Hirohashi K., Tanaka H., Tsukamoto T., Hamba H., et al. Patterns of and risk factors for recurrence after liver resection for well-differentiated hepatocellular carcinoma: a special reference to multicentric carcinogenesis after operation. Hepatogastroenterology 1999, 46:3212-3215.
44. Kaido T., Takada Y., Egawa H., Uemoto S. The influence of intraoperative homologous blood transfusion on prognosis after liver transplantation for hepatocellular carcinoma. Hepatogastroenterology 2009, 56:808-812.
45. Ghio M., Contini P., Mazzei C., Brenci S., Barberis G., Filaci G., et al. Soluble HLA class I, HLA class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions. Blood 1999, 93:1770-1777.
46. Tomimaru Y., Wada H., Marubashi S., Kobayashi S., Eguchi H., Takeda Y., et al. Fresh frozen plasma transfusion does not affect outcomes following hepatic resection for hepatocellular carcinoma. World J Gastroenterol 2010, 16:5603-5610.
47. Shiba H., Misawa T., Fujiwara Y., Futagawa Y., Furukawa K., Haruki K., et al. Negative impact of fresh-frozen plasma transfusion on prognosis of pancreatic ductal adenocarcinoma after pancreatic resection. Anticancer Res 2013, 33:4041-4047.
48. Shiba H., Ishida Y., Haruki K., Furukawa K., Fujiwara Y., Iwase R., et al. Negative impact of fresh-frozen plasma transfusion on prognosis after hepatic resection for liver metastases from colorectal cancer. Anticancer Res 2013, 33:2723-2728.